⌕
Neurocrine Biosciences · NBIX · Nasdaq
Tenet 65 · Solid
Compare
$165.31−1.25%At closeTenet 65 · Solid
$165.31−2.09 (−1.25%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Neurocrine Biosciences (NBIX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 16, 2026 · 10:46 ET
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

● Defense WorldNov 16, 2026 · 03:59 ETEARNINGS EXPECTED BY FEB 8
Eurizon Capital SGR S.p.A. Sells 10,154 Shares of Neurocrine Biosciences, Inc. $NBIX

Eurizon Capital SGR S.p.A. trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 20.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned…

● Zacks Investment ResearchNov 10, 2026 · 16:41 ET
NBIX or GRDN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks presents investors with the…

● PRNewsWireNov 10, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London at 3:30 p.m. Greenwic…

● Zacks Investment ResearchNov 9, 2026 · 13:46 ET
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.…

● Zacks Investment ResearchNov 9, 2026 · 13:01 ETEARNINGS EXPECTED BY FEB 8
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy

Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.…

● Zacks Investment ResearchNov 9, 2026 · 12:40 ET
NBIX vs. GRDN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the best option for those l…

● Zacks Investment ResearchNov 9, 2026 · 10:56 ETEARNINGS EXPECTED BY FEB 8
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earni…

● PRNewsWireNov 5, 2026 · 08:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6 to 2.0 A separate p…

● Defense WorldNov 5, 2026 · 04:52 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences, Inc. $NBIX Shares Newly Bought by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange …

● Seeking AlphaNov 5, 2026 · 04:05 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences: Breaking Down A Solid Quarter

Neurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of $3.29 and revenue up 41% to $1.12 billion. INGREZZA remains NBIX's primary growth driver, posting 17% year-over-year sales growth to $…

● Seeking AlphaNov 4, 2026 · 10:05 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation

Neurocrine Biosciences is in an attractive growth phase, driven by strong INGREZZA sales and rapid expansion of CRENESSITY and VYKAT XR. Q3 2026 revenue grew 41% year-over-year to $1.123 billion, reflecting increasing pr…

● Seeking AlphaNov 4, 2026 · 08:45 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free

Neurocrine Biosciences is reiterated as a buy with a new fair value of $195.80, 19% above the recent price. The investment thesis centers on NBIX's underappreciated early research engine, now valued using an industry pro…

● Defense WorldNov 4, 2026 · 03:57 ET
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Breaks Above Two Hundred Day Moving Average on Insider Selling

Neurocrine Biosciences, Inc. (NASDAQ: NBIX - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday after an insider bought additional shares in the company. The stock has a 200-…

● PRNewsWireNov 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8 in Colorado Sp…

● Zacks Investment ResearchNov 3, 2026 · 12:16 ETEARNINGS EXPECTED BY FEB 8
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View

Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.…

● MarketBeatNov 2, 2026 · 21:15 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences Q3 Earnings Call Highlights

Neurocrine Biosciences NASDAQ: NBIX reported record third-quarter net product sales exceeding $1.1 billion and record operating profitability, supported by growth across its three marketed medicines: INGREZZA, CRENESSITY…

● Seeking AlphaNov 2, 2026 · 21:08 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 2, 2026 · 20:11 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $3.29 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.04 per share a year ago.…

● Zacks Investment ResearchNov 2, 2026 · 19:31 ETEARNINGS EXPECTED BY FEB 8
Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and…

● PRNewsWireNov 2, 2026 · 16:49 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, In…

● Zacks Investment ResearchNov 2, 2026 · 10:41 ET
Here's Why Neurocrine Biosciences (NBIX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

● Zacks Investment ResearchOct 30, 2026 · 10:46 ET
Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

● PRNewsWireOct 30, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

BootCAHmp® delivers evidence-based education to strengthen understanding of classic congenital adrenal hyperplasia through interactive learning and real-world patient cases DiscoverCAH™ provides immersive virtual experie…

● Zacks Investment ResearchOct 26, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● PRNewsWireOct 26, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with INGREZZA®(valbenazine…

● PRNewsWireOct 22, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patients and families bey…

● PRNewsWireOct 20, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to …

● PRNewsWireOct 16, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showed growth and bone-ag…

● PRNewsWireOct 12, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial res…

Expected by Feb 8. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.